Moderna and Merck advance cancer vaccines

Moderna and Merck have announced positive results from a large trial of their personalized cancer vaccine, intismeran autogene, which aims to prevent melanoma recurrence after surgery. The vaccine, used alongside Keytruda immunotherapy, showed promise in reducing the risk of cancer returning and spreading, with ongoing trials exploring its use in other tumor types. Experts consider this a significant advancement in mRNA cancer treatments, potentially benefiting thousands of melanoma patients within a few years.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل